Coldstream Capital Management Inc. Sells 321 Shares of Repligen Corporation $RGEN

Coldstream Capital Management Inc. reduced its position in shares of Repligen Corporation (NASDAQ:RGEN) by 14.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,933 shares of the biotechnology company’s stock after selling 321 shares during the period. Coldstream Capital Management Inc.’s holdings in Repligen were worth $240,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after purchasing an additional 430,039 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after acquiring an additional 400,970 shares during the last quarter. Geneva Capital Management LLC raised its stake in Repligen by 239.6% during the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after acquiring an additional 343,991 shares in the last quarter. Nuveen LLC bought a new position in shares of Repligen in the first quarter worth about $35,536,000. Finally, Primecap Management Co. CA boosted its stake in shares of Repligen by 348.1% in the 2nd quarter. Primecap Management Co. CA now owns 138,278 shares of the biotechnology company’s stock valued at $17,199,000 after purchasing an additional 107,420 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 20,000 shares of the stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the sale, the director directly owned 80,743 shares in the company, valued at $12,483,675.23. This represents a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 49,382 shares of company stock worth $7,676,802. Insiders own 1.20% of the company’s stock.

Repligen Trading Down 0.0%

Shares of RGEN stock opened at $171.11 on Friday. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.63 billion, a price-to-earnings ratio of 8,559.78, a PEG ratio of 3.32 and a beta of 1.15. The stock has a 50-day moving average of $149.72 and a 200-day moving average of $131.77.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.42 by $0.04. The business had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The firm’s revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RGEN shares. Canaccord Genuity Group upped their price objective on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. HSBC assumed coverage on shares of Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 price target for the company. Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Barclays boosted their price objective on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.